Primary: to assess the long-term (4 and 5 years of age) efficacy of intra-amniotic administrations of ER004 on sweating ability (sweat volume) in male XLHED subjects with a null mutation in EDA. Secondary: ? To assess the long-term efficacy of intra-amniotic administrations of ER004 on sweat pore density, dentition, dry eyes issues, eczema, salivation and XLHED-related hospitalization in male subjects with XLHED ? To assess the long-term safety of intra-amniotic administrations of ER004 in male subjects with XLHED
Not Available
What is the full name of this clinical trial?
Evaluation of Safety and Efficacy of ER004 Post-Intra-Amniotic Treatment in Males with XLHED